Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the potency of highly cytotoxic payloads to deliver targeted cancer therapies. Manufacturing ADCs remains demanding: extremely potent payloads require stringent containment, organic solvents can promote aggregation, and achieving an optimal drug-to-antibody ratio (DAR) places pressure on manufacturers.
The white paper reviews these hurdles and explains how closed, single-use systems can support reliable and scalable ADC production. It also provides results for an extractables study of single-use tubing and filter components used in settings relevant to ADC manufacturing.
Copyright © 2025 American Chemical Society | 1155 Sixteenth Street NW | Washington, DC 20036 | View our Privacy Policy